Rani Therapeutics Holdings, Inc. (RANI) stock
RANINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/3051% above fair value
$0.58−0.07 (-10.42%)
Close on Nov 19, 2026Market cap $80.93MP/E –Yield –
Rani Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Rani Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$20.34M. For fiscal 2025 it was -$18.80M. The highest annual figure on record is -$16.16M in fiscal 2020.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$18.80M | – |
| FY2024 | Dec 31, 2024 | -$35.76M | – |
| FY2023 | Dec 31, 2023 | -$52.47M | – |
| FY2022 | Dec 31, 2022 | -$48.13M | – |
| FY2021 | Dec 31, 2021 | -$32.75M | – |
| FY2020 | Dec 31, 2020 | -$16.16M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$9.06M | – |
| Q1 FY2026 | Mar 31, 2026 | -$6.51M | – |
| Q4 FY2025 | Dec 31, 2025 | $294.00K | – |
| Q3 FY2025 | Sep 30, 2025 | -$5.06M | – |
| Q2 FY2025 | Jun 30, 2025 | -$5.83M | – |
| Q1 FY2025 | Mar 31, 2025 | -$8.20M | – |
| Q4 FY2024 | Dec 31, 2024 | -$8.69M | – |
| Q3 FY2024 | Sep 30, 2024 | -$8.54M | – |
| Q2 FY2024 | Jun 30, 2024 | -$9.12M | – |
| Q1 FY2024 | Mar 31, 2024 | -$9.42M | – |
| Q4 FY2023 | Dec 31, 2023 | -$12.65M | – |
| Q3 FY2023 | Sep 30, 2023 | -$14.78M | – |
| Q2 FY2023 | Jun 30, 2023 | -$12.64M | – |
| Q1 FY2023 | Mar 31, 2023 | -$12.40M | – |
| Q4 FY2022 | Dec 31, 2022 | -$15.16M | – |
| Q3 FY2022 | Sep 30, 2022 | -$12.65M | – |
| Q2 FY2022 | Jun 30, 2022 | -$10.71M | – |
| Q1 FY2022 | Mar 31, 2022 | -$9.61M | – |
| Q4 FY2021 | Dec 31, 2021 | -$11.72M | – |
| Q3 FY2021 | Sep 30, 2021 | -$11.12M | -1759.7% |
| Q2 FY2021 | Jun 30, 2021 | -$5.76M | – |
| Q1 FY2021 | Mar 31, 2021 | -$4.15M | – |
| Q4 FY2020 | Dec 31, 2020 | -$6.96M | – |
| Q3 FY2020 | Sep 30, 2020 | $670.00K | – |
See a number that looks wrong?